Document:

Exhibit

Exhibit 10.4

Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.

 

August 6, 2019

Prasco, LLC
6125 Commerce Court
Mason, Ohio 45040
Attention: Chairman 

Re:    Termination of Distribution and Supply Agreement

Dear Mr. Arington:

This letter (this “Letter”) is in reference to tn Distribution and Supply Agreement, by and between AMAG Pharmaceuticals, Inc. (“AMAG”) and Prasco, LLC (“Prasco”), dated as of December 20, 2017 (the “Agreement”) pursuant to which Prasco purchased and sold an authorized generic version of AMAG’s Makena® (hydroxyprogesterone caproate injection).  All capitalized terms used but not defined herein shall have the meaning as set forth in the Agreement.
 
AMAG and Prasco have mutually determined that the arrangements contemplated by the Agreement are no longer in their best interests due to the commercial viability of the Product and, therefore, AMAG and Prasco have mutually agreed to terminate the Agreement pursuant to Section 10.4 of the Agreement effective as of August 6, 2019 (the “Termination Date”).  The Parties hereby agree that, except as set forth in Section 12.2 of the Agreement and the agreements set forth in this Letter, the Agreement, including all of the rights and obligations of AMAG and Prasco thereunder, shall terminate and be of no further force and effect, and neither AMAG nor any of its affiliates has or will have any further liability or obligation to Prasco or any of its affiliates in connection with the Agreement effective as of the Termination Date.

In connection with the termination of the Agreement: (1) notwithstanding Section 10.8(i) of the Agreement, any outstanding Firm Order shall be automatically cancelled, and Manufacturer shall have no further obligation to supply Product, and Prasco shall have no further obligation to purchase Product, (2) the authorized sell-off period set forth in Section 10.8(iii) shall be extended such that Prasco shall be authorized and permitted to sell any remaining inventory of Product following the Termination Date [***] (the “Sell-Off Period”) subject to its obligations to share profits with AMAG pursuant to the Agreement, and (3) the Parties shall cooperate to effect an orderly wind-down of activities under the Agreement, including, at [***], the return or destruction of any remaining inventory not sold during the Sell-Off Period and [***] for such remaining inventory.

The terms of this Letter shall be deemed Confidential Information under the Agreement, and shall be subject to the provisions of Article 11 of the Agreement.  This Letter may be executed and delivered in one or more counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument.  Any counterpart which may be delivered by facsimile or e-mail PDF shall be deemed the equivalent of an originally signed counterpart.  This Letter shall constitute the entire agreement among the Parties with respect to the subject matter hereof and shall supersede all previous negotiations, commitments and writings with respect to such subject matter. Each Party hereto acknowledges that, in entering into this Letter, it has not relied upon any representation or warranty made by the other Party, or any other person on such other Party’s behalf other than as set forth herein.  This Letter shall be governed by and construed in accordance with the laws of the State of New York, without regard to conflict of law principles.

[Signature Page Follows]

Please acknowledge your agreement to the foregoing by signing your name in the space provided below and returning a copy to me.

Very truly yours,
AMAG PHARMACEUTICALS, INC.

By:_/s/ Ted Myles________________________
Name: Ted Myles
Title: EVP & Chief Financial Officer

ACCEPTED AND AGREED

PRASCO, LLC

By:__/s/ E. Thomas Arington______
Name: E. Thomas Arington
Title: Chairman

Cc: 
Jonathan M. Lapps
Scott Fruechtemeyer
Tony Casciano
Joseph D. Vittiglio
Kyle HaraldsenExhibit 4.1

 

RBC BEARINGS INCORPORATED

 

Description of Capital Stock

 

General

 

The Amended and Restated
Certificate of Incorporation of RBC Bearings Incorporated, a Delaware corporation, authorizes RBC to issue (i) 60,000,000 shares
of Common Stock, par value $0.01 per share, and (ii) 10,000,000 shares of Preferred Stock, $0.01 par value per share.

 

Common Stock

 

Voting Rights.
Each outstanding share of Common Stock is entitled to one vote on all matters submitted to a vote of RBC’s stockholders.
Shares of Common Stock are not entitled to cumulative voting. RBC has a staggered Board of Directors divided into three classes,
each of which is up for election every third year so that each director serves a three-year term until his or her class comes up
for election. Directors are elected by a majority of the votes cast.

 

Dividends.
Subject to the dividend rights of the holders of any outstanding Preferred Stock, the holders of shares of Common Stock are entitled
to receive ratably dividends out of assets legally available therefor at such times and in such amounts as RBC’s Board of
Directors may from time to time determine. RBC does not currently pay regular dividends on the Common Stock.

 

Liquidation Rights.
Upon the liquidation, dissolution or winding up of RBC’s affairs and subject to the liquidation rights of the holders of
any outstanding Preferred Stock, the holders of shares of Common Stock are entitled to share ratably in RBC’s assets that
are legally available for distribution after payment of all RBC’s debts and liabilities.

 

No Other Rights.
The Common Stock is not convertible or redeemable, has no sinking fund rights, and is not entitled to preemptive rights to purchase,
subscribe for or otherwise acquire any unissued or treasury shares or other securities. Delaware law does not require stockholder
approval for any issuance of authorized shares. However, the listing requirements of Nasdaq (which would apply so long as the Common
Stock is listed on Nasdaq) require stockholder approval of certain issuances equal to or exceeding 20% of the then outstanding
voting power or then outstanding number of shares of Common Stock.

 

Listing.
Shares of Common Stock are listed on the Nasdaq National Market System under the symbol “ROLL.”

 

Transfer Agent.
The transfer agent for the Common Stock is Computershare Trust Company, N.A.

 

Preferred Stock

 

The Preferred Stock
may be issued from time to time in one or more series. RBC’s Board of Directors, without further action by the stockholders,
has the authority to determine or alter the powers, preferences, rights, qualifications, limitations and restrictions granted to
or imposed on unissued shares of Preferred Stock, and to determine the number of shares constituting any series of Preferred Stock.
Preferred Stock terms that the Board of Directors could establish include those relating to voting, dividends, redemption, conversion,
exchange, sinking fund, preemption, liquidation and other rights, preferences and privileges.

 

At this time, RBC has
not issued any shares of Preferred Stock or established the terms of any series of Preferred Stock.

 

     

     

    

 

Anti-Takeover Provisions of RBC’s
Charter Documents

 

Provisions of RBC’s
certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control that
stockholders may consider favorable, including transactions that might benefit stockholders or in which stockholders might otherwise
receive a premium for their shares. These provisions may also prevent or frustrate attempts by RBC’s stockholders to replace
or remove management. These include:

 

		●	The Board of Directors is divided into three classes so that each director comes up for re-election
only once in any three-year period;

 

		●	The Board of Directors has the ability to do the following without stockholder approval: (i) issue
additional shares of Common Stock, (ii) set the term of and issue Preferred Stock, (iii) amend the bylaws, and (iv) fill vacancies
on the Board of Directors;

 

		●	Special meetings of the stockholders may be called only by the Board of Directors; and

 

		●	Stockholder action may be taken only at an annual or special meeting and not by written consent.

 

Anti-Takeover Effects of Delaware Law

 

RBC is subject to
Section 203 of the Delaware General Corporation Law, which prohibits a publicly held Delaware corporation from engaging in a “business
combination” with any “interested stockholder” for a period of three years after the date of the transaction
in which the person became an interested stockholder, unless:

 

		(1)	such transaction is approved by the corporation’s board of directors prior to the date the
interested stockholder obtains such status,

 

		(2)	upon consummation of such transaction, the interested stockholder beneficially owned at least 85%
of the voting stock of the corporation outstanding at the time the transaction commenced, or

 

		(3)	the business combination is approved by both the corporation’s board of directors and the
affirmative vote of at least 66-2/3% of the outstanding voting stock that is not owned by the interested stockholder.

 

A “business
combination” includes mergers, asset sales and other transactions resulting in financial benefit to the interested stockholder.
An “interested stockholder” is a person who, together with affiliates and associates, owns (or within three years,
did own) beneficially 15% or more of the corporation’s voting stock.

 

Section 203 could
prohibit or delay mergers or other takeover or change in control attempts with respect to RBC and, accordingly, may discourage
attempts to acquire RBC even though such a transaction may offer stockholders the opportunity to sell their stock at a price above
the prevailing market price.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}]]